ANAB 8-K
Anaptysbio, Inc (ANAB)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On March 3, 2026, AnaptysBio, Inc. (“AnaptysBio”) issued a press release announcing its financial results for the three months and year ended December 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 2.02, including Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document filed by AnaptysBio with the Securities and Exchange Commission, whether made before or after the date of this Current Report on Form 8-K, regardless of any general incorporation language in such filing (or any reference to this Current Report on Form 8-K generally), except as shall be expressly set forth by specific reference in such filing.
Item 7.01 Regulation FD.
AnaptysBio is furnishing the Presentation, a full copy is attached hereto as Exhibit 99.2.
The information in this Item 7.01, including Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit Number |
Exhibit Title or Description |
Press release issued by AnaptysBio, Inc. regarding its financial results for the three months and year ended December 31, 2025, dated March 3, 2026. |
|
Anaptys Corporate Presentation March 2026 |
|
104 |
Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
AnaptysBio, Inc. |
|
|
|
|
Date: |
March 3, 2026 |
By: |
/s/ Dennis Mulroy |
|
|
|
Name: Dennis Mulroy |
Anaptys Provides Update on Business Separation and
Announces Fourth Quarter and Full Year 2025 Financial Results
SAN DIEGO, March 3, 2026 — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today provided an update on the potential spin-off of its biopharma operations and reported financial results for the fourth quarter and year ended Dec. 31, 2025.
“We are approaching a defining inflection point for Anaptys, as we plan to spin-off in Q2 2026 our wholly owned biopharma portfolio into a public company, to be called First Tracks Biotherapeutics, to unlock and amplify value for investors across two distinct sets of assets,” said Daniel Faga, president and chief executive officer of Anaptys. “In our royalty portfolio, Jemperli exited Q4 2025 on a ~$1.4 billion annualized run rate, reinforcing GSK’s peak sales guidance of far more than $2.7 billion2 in monotherapy indications. At the same time, our biopharma portfolio is advancing multiple attractive, high-potential assets, including ANB033, which has pipeline-in-a-product potential, initially in a Phase 1b trial for both celiac disease and eosinophilic esophagitis.”
INTENT TO SEPARATE BUSINESS
AnaptysBio (formerly referred to as “Royalty Management Co”)
GSK Jemperli Financial Collaboration
o AZUR-1 – pivotal Phase 2 – dostarlimab monotherapy in untreated stage II/III dMMR/MSI-H locally advanced rectal cancer
o AZUR-2 – pivotal Phase 3 – dostarlimab versus standard of care in untreated TN40 or stage III dMMR/ MSI-H resectable colon cancer
o AZUR-4 – Phase 2 – dostarlimab plus chemotherapy versus standard of care (chemotherapy) in untreated stage III MMRp/MSS resectable colon cancer
o JADE – pivotal Phase 3 – dostarlimab monotherapy versus placebo in locally advanced unresected head and neck squamous cell carcinoma (PD-L1 hiPghD-L1 CPS≥1) post chemoradiation
Vanda Imsidolimab Financial Collaboration
First Tracks Biotherapeutics (formerly referred to as “Biopharma Co”)
ANB033 (CD122 antagonist)
Rosnilimab (Pathogenic T Cell Depleter)
ANB101 (BDCA2 modulator)
FINANCIAL UPDATES
Cash Position and Stock Repurchase Program
Fourth Quarter and Full Year 2025 Financial Results
About Anaptys
Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. The company’s pipeline includes rosnilimab, a pathogenic T cell depleter, which has completed a Phase 2b trial for rheumatoid arthritis; ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease and eosinophilic esophagitis; and ANB101, a BDCA2 modulator, in a Phase 1a trial. Anaptys has also discovered and out-licensed in financial collaborations multiple therapeutic antibodies, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) to GSK and an IL-36R antagonist (imsidolimab) to Vanda Pharmaceuticals. To learn more, visit www.AnaptysBio.com or follow us on LinkedIn.
Anaptys recently announced the intent to separate its biopharma operations from its substantial royalty assets by year-end 2026, enabling investors to align their investment philosophies and portfolio allocation with the strategic opportunities and financial objectives of each company. Learn more at https://ir.anaptysbio.com/news-releases/news-release-details/anaptys-announces-intent-separate-biopharma-operations.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the timing of the release of data from the Company’s clinical trials, including initial data from ANB033's Phase 1b clinical trial in celiac disease and initial data from ANB033's Phase 1b clinical trial in eosinophilic esophagitis; expectations regarding the structure, infrastructure, timing and taxation of the proposed separation of companies; timing of paydown of financial obligations to Sagard; whether any partnership with rosnilimab will take place; the potential to receive any royalties or milestone payments from the Vanda Pharmaceuticals license agreement; the potential to receive any additional milestones or royalties from the GSK collaboration and timing therefor; and the projected cash runway for First Tracks Biotherapeutics. Statements including words such as “plan,” “continue,” “expect,” or “ongoing” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause the company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company’s ability to advance its product candidates, obtain regulatory approval of and ultimately commercialize its product candidates, the timing and results of preclinical and clinical trials, the company’s ability to fund development activities and achieve development goals, the company’s ability to protect intellectual property, the ability to effect the separation of companies as described herein and other risks and uncertainties described under the heading “Risk Factors” in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
Contact:
Nick Montemarano
Executive Director, Investor Relations
858.732.0178
[email protected]
_______________________________________
AnaptysBio, Inc.
Consolidated Balance Sheets
(in thousands, except par value data)
|
|
December 31, 2025 |
|
|
December 31, 2024 |
|
||
ASSETS |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
238,196 |
|
|
$ |
123,080 |
|
Receivables from collaborative partners |
|
|
33,850 |
|
|
|
40,765 |
|
Short-term investments |
|
|
73,442 |
|
|
|
262,293 |
|
Prepaid expenses and other current assets |
|
|
4,762 |
|
|
|
5,738 |
|
Total current assets |
|
|
350,250 |
|
|
|
431,876 |
|
Property and equipment, net |
|
|
1,370 |
|
|
|
1,849 |
|
Operating lease right-of-use assets |
|
|
12,519 |
|
|
|
14,383 |
|
Long-term investments |
|
|
— |
|
|
|
35,470 |
|
Other long-term assets |
|
|
256 |
|
|
|
256 |
|
Total assets |
|
$ |
364,395 |
|
|
$ |
483,834 |
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
3,871 |
|
|
$ |
4,002 |
|
Accrued expenses |
|
|
32,674 |
|
|
|
39,501 |
|
Current portion of operating lease liability |
|
|
2,080 |
|
|
|
1,925 |
|
Total current liabilities |
|
|
38,625 |
|
|
|
45,428 |
|
Liability related to sale of future royalties |
|
|
276,528 |
|
|
|
353,426 |
|
Operating lease liability, net of current portion |
|
|
12,032 |
|
|
|
14,112 |
|
Stockholders’ equity: |
|
|
|
|
|
|
||
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at December 31, 2025 and December 31, 2024, respectively |
|
|
— |
|
|
|
— |
|
Common stock, $0.001 par value, 500,000 shares authorized, 28,019 shares and 30,473 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively |
|
|
28 |
|
|
|
30 |
|
Additional paid in capital |
|
|
809,765 |
|
|
|
829,860 |
|
Accumulated other comprehensive (loss) gain |
|
|
(24 |
) |
|
|
305 |
|
Accumulated deficit |
|
|
(772,559 |
) |
|
|
(759,327 |
) |
Total stockholders’ equity |
|
|
37,210 |
|
|
|
70,868 |
|
Total liabilities and stockholders’ equity |
|
$ |
364,395 |
|
|
$ |
483,834 |
|
AnaptysBio, Inc.
Consolidated Statements of Operations and Comprehensive Income (Loss)
(in thousands, except per share data)
|
|
Three Months Ended |
|
|
Year Ended |
|
||||||||||
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
Collaboration revenue |
|
$ |
108,249 |
|
|
$ |
43,113 |
|
|
$ |
234,603 |
|
|
$ |
91,280 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development |
|
|
25,559 |
|
|
|
42,589 |
|
|
|
135,970 |
|
|
|
163,840 |
|
General and administrative |
|
|
15,789 |
|
|
|
10,194 |
|
|
|
50,737 |
|
|
|
42,389 |
|
Total operating expenses |
|
|
41,348 |
|
|
|
52,783 |
|
|
|
186,707 |
|
|
|
206,229 |
|
Income (loss) from operations |
|
|
66,901 |
|
|
|
(9,670 |
) |
|
|
47,896 |
|
|
|
(114,949 |
) |
Other (expense) income, net: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest income |
|
|
2,508 |
|
|
|
5,263 |
|
|
|
13,499 |
|
|
|
19,794 |
|
Non-cash interest expense for the sale of future royalties |
|
|
(19,711 |
) |
|
|
(17,404 |
) |
|
|
(79,893 |
) |
|
|
(50,087 |
) |
Other (expense) income, net |
|
|
(3 |
) |
|
|
21 |
|
|
|
5,430 |
|
|
|
14 |
|
Total other (expense) income, net |
|
|
(17,206 |
) |
|
|
(12,120 |
) |
|
|
(60,964 |
) |
|
|
(30,279 |
) |
Gain (loss) before income taxes |
|
|
49,695 |
|
|
|
(21,790 |
) |
|
|
(13,068 |
) |
|
|
(145,228 |
) |
(Provision) benefit for income taxes |
|
|
(81 |
) |
|
|
6 |
|
|
|
(164 |
) |
|
|
(3 |
) |
Net income (loss) |
|
|
49,614 |
|
|
|
(21,784 |
) |
|
|
(13,232 |
) |
|
|
(145,231 |
) |
Other comprehensive income (loss): |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Unrealized (loss) gain on available for sale securities |
|
|
(71 |
) |
|
|
(454 |
) |
|
|
(329 |
) |
|
|
1,102 |
|
Comprehensive income (loss) |
|
$ |
49,543 |
|
|
$ |
(22,238 |
) |
|
$ |
(13,561 |
) |
|
$ |
(144,129 |
) |
Net income (loss) per common share: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic |
|
$ |
1.79 |
|
|
$ |
(0.72 |
) |
|
$ |
(0.46 |
) |
|
$ |
(5.12 |
) |
Diluted |
|
$ |
1.58 |
|
|
$ |
(0.72 |
) |
|
$ |
(0.46 |
) |
|
$ |
(5.12 |
) |
Weighted-average number of shares outstanding: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic |
|
|
27,789 |
|
|
|
30,448 |
|
|
|
28,758 |
|
|
|
28,382 |
|
Diluted |
|
|
31,343 |
|
|
|
30,448 |
|
|
|
28,758 |
|
|
|
28,382 |
|
